Jeffrey Weber, MD, PhD, Describes Unmet Needs for Patients with Melanoma


Jeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.

Jeffrey Weber, MD, PhD, of NYU Langone Health spoke with CancerNetwork regarding the unmet needs for patients with melanoma and the binary treatment options for this group of patients.


So, the challenge in our business is which treatment to give them after surgery, what adjuvant treatment? It comes down to a particular binary choice, we either give them PD-1 antibodies like nivolumab (Opdivo) or pembrolizumab (Keytruda) or you give them BRAF/MEK drugs and dabrafenib/trametinib are the 2 approved for that indication. So, the unmet need is what do you do after surgery for a high-risk patient? The other unmet need is what do you do in metastatic disease? And there, it comes down to what’s your front-line treatment, and generally that’s immunotherapy. Then the question is, if you’re BRAF-mutated, what do you do if you fail immunotherapy? If you fail (ipilimumab [Yervoy] plus nivolumab), you don’t have a lot of options. So, that’s where BRAF/MEK drugs will come in handy and have been very useful.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Related Content